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Background-—Off-target properties of ticagrelor might reduce microvascular injury and improve clinical outcome in patients with
ST-segment–elevation myocardial infarction. The REDUCE-MVI (Evaluation of Microvascular Injury in Revascularized Patients with
ST-Segment–Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel) trial reported no beneﬁt of ticagrelor
regarding microvascular function at 1 month. We now present the follow-up data up to 1.5 years.
Methods and Results-—We randomized 110 patients with ST-segment–elevation myocardial infarction to either ticagrelor 90 mg
twice daily or prasugrel 10 mg once a day. Platelet inhibition and peripheral endothelial function measurements including calcula-
tion of the reactive hyperemia index and clinical follow-up were obtained up to 1.5 years. Major adverse clinical events and bleedings
were scored. An intention to treat and a per-protocol analysis were performed. There were no between-group differences in platelet
inhibition and endothelial function. At 1 year the reactive hyperemia index in the ticagrelor group was 0.660.26 versus 0.61
0.28 in the prasugrel group (P=0.31). Platelet inhibition was lower at 1 month versus 1 year in the total study population (61% [42%–
81%] versus 83% [61%–95%]; P<0.001), and per-protocol platelet inhibition was higher in patients randomized to ticagrelor versus
prasugrel at 1 year (91% [83%–97%] versus 82% [65%–92%]; P=0.002). There was an improvement in intention to treat endothelial
function in patients randomized to ticagrelor (P=0.03) but not in patients randomized to prasugrel (P=0.88). Major adverse clinical
events (10% versus 14%; P=0.54) and bleedings (47% versus 63%; P=0.10) were similar in the intention-to-treat analysis in both groups.
Conclusions-—Platelet inhibition at 1 year was higher in the ticagrelor group, without an accompanying increase in bleedings.
Endothelial function improved over time in ticagrelor patients, while it did not change in the prasugrel group.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique Identiﬁer: NCT02422888. ( J Am Heart Assoc. 2020;9:
e014411. DOI: 10.1161/JAHA.119.014411.)
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I n patients with ST-segment–elevation myocardial infarc-tion (STEMI), the preferred treatment is immediate percu-
taneous coronary intervention of the culprit coronary artery
with antiplatelet therapy. Currently, the P2Y12 inhibitors
ticagrelor and prasugrel are recommended as antiplatelet
therapy both in the acute setting and as maintenance
therapy.1 Despite successful revascularization, microvascular
injury occurs in about half of patients with STEMI,2 and its
presence is associated with poor outcome.3 It has been
proposed that equilibrative nucleoside transporter-1 inhibition
of ticagrelor could cause elevated adenosine levels and
thereby may preserve endothelial function and prevent
microvascular injury in STEMI with potentially better clinical
outcome.4–7 The REDUCE-MVI (Evaluation of Microvascular
Injury in Revascularized Patients with ST-Segment–Elevation
Myocardial Infarction Treated With Ticagrelor Versus Prasug-
rel) trial, was the ﬁrst randomized trial that investigated the
potential effect of ticagrelor versus prasugrel maintenance
therapy on microvascular injury in patients with STEMI
assessed by the index of microcirculatory resistance (IMR).8
Ticagrelor as compared with prasugrel did not show a
beneﬁcial effect with regard to the IMR in the culprit vessel
1 month after the index event.
Recently, it was reported that ticagrelor treatment at
steady state improves peripheral endothelial function
assessed by reactive hyperemic peripheral arterial tonometry
(RH-PAT) (EndoPAT, Itamar Medical Ltd., Caesarea, Israel) in
patients with a previous myocardial infarction.9 However,
whether ticagrelor maintenance therapy provides beneﬁt over
prasugrel with regard to long-term peripheral endothelial
function is unknown. Also, comparative randomized data on
platelet inhibition with either ticagrelor or prasugrel mainte-
nance therapy are currently not available.
Here, we present the 1.5-year clinical follow-up of the
REDUCE-MVI trial, including serial measurements of platelet
inhibition and peripheral endothelial function as assessed by
means of RH-PAT.
Methods
Study Design and Outcome Measures
The current study is the predeﬁned long-term clinical follow-
up of the REDUCE-MVI Trial.8 This investigator-initiated,
randomized, multicenter trial compared the potential effects
of ticagrelor versus prasugrel maintenance therapy on
microvascular injury in patients with STEMI. The study trial
design10 and the short-term primary outcome with IMR at 1
month and cardiac magnetic resonance imaging parameters
as secondary outcomes were previously published.8 In the
present study, we describe patient characteristics, platelet
inhibition, patient symptoms, and clinical outcome (including
bleeding) at 1- and 1.5-year follow-up. Furthermore, we
present the serial peripheral endothelial function measure-
ments by means of RH-PAT. The study protocol complies
with the Declaration of Helsinki, was approved by the
institutional review board (local ethics committee), and
conforms to the International Conference on Harmoniza-
tion/Good Clinical Practice standards. The trial is registered
at URL: https://clinicaltrials.gov, with the unique identiﬁer:
NCT02422888. The data that support the ﬁndings of this
study are available from the corresponding author upon
reasonable request.
The trial was conducted at 6 centers in the Netherlands and
Spain. In short, patients with a STEMI presenting <12 hours
after onset of symptoms were considered eligible. All patients
had multivessel disease, were <75 years old, and received a
loading dose of ticagrelor (180 mg). Table S1 includes a
complete overview of the inclusion and exclusion criteria. After
providing written informed consent, patients were randomized
in a 1:1 fashion to either ticagrelor 90 mg twice daily or
prasugrel 10 mg once daily as maintenance therapy for 1 year
using a secure web-based electronic case report form system
(Castor EDC, Amsterdam, the Netherlands). When the physi-
cian responsible for the clinical care of the patient decided that
the randomized study drug was contraindicated, the patient
could stop or switch their P2Y12 inhibitor before 1 year and
continued follow-up for the further duration of the study.
Concomitant medical therapy after 1 year was left to the
discretion of the treating physician and was based on current
Clinical Perspective
What Is New?
• This study reports the long-term follow-up of patients with
ST-segment–elevation myocardial infarction randomized to
ticagrelor versus prasugrel maintenance therapy and
demonstrated a higher platelet inhibition at 1 year with an
improvement in peripheral endothelial function in the
ticagrelor group. Interestingly, platelet inhibition was signif-
icantly lower at 1-month versus 1-year follow-up.
What Are the Clinical Implications?
• In patients with ST-segment–elevation myocardial infarction
on P2Y12 inhibitor maintenance therapy, it is clinically of
great importance to seek for an optimal balance in the
beneﬁt–risk ratio of platelet inhibition.
• The lower platelet inhibition at 1 month could be explained
either by a hampered platelet inhibition in the subacute
phase after ST-segment–elevation myocardial infarction
(with an associated increased risk of ischemic events) or
by an exceedingly ampliﬁed platelet inhibition after 1 year of
P2Y12 inhibitor treatment (with an associated increased
bleeding risk).
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guidelines.1 Follow-up at 1 year was performed before
cessation of the P2Y12 inhibitor and at 1.5 years was
performed to examine patient outcomes after cessation of
the P2Y12 inhibitor. We assessed medication compliance each
visit with a questionnaire.
Laboratory Measurements and Platelet Inhibition
Blood samples were collected in the acute setting and at all
follow-up visits and were subsequently sent to the local
laboratory to assess standard clinical parameters (eg, blood
count, lipid spectrum, and inﬂammatory status). In addition, in
the acute setting during the index procedure, at 1 month
during the follow-up coronary angiogram, and at 1-year follow-
up, we quantiﬁed platelet aggregation by percentage of
inhibition by analysis of the collected blood samples with the
VerifyNow System (Accumetrics, San Diego, CA). Blood was
collected in a citrate-coated tube, and the ﬁrst 2 to 4 mL of
blood was discarded to prevent spontaneous platelet activa-
tion. The percentage of platelet inhibition was calculated as
follows: ([BASEPRU]/BASE)9100 as previously described.11
We assumed a high platelet reactivity when the P2Y12
reaction units (PRU) exceeded 20812,13 and a low platelet
reactivity when PRU was below 85.14 As an alternative
threshold we also described PRU <95, as this cutoff value is
known to be associated with an increased bleeding risk.15
Peripheral Endothelial Function Measurements
To assess peripheral endothelial function, RH-PAT using the
EndoPAT device was performed in the acute setting
(<24 hours after presentation), at 1 month, at 1 year, and
at 1.5-year follow-up. The EndoPAT device measures the
endothelium-mediated changes in vascular tone with each
arterial pulsation by 2 plethysmographic probes placed on the
index ﬁngers. RH-PAT measurements were performed in the
contralateral arm used for coronary angiographic access: (1)
under resting conditions for 5 minutes; (2) after inﬂation of a
blood cuff on the study arm, while the contralateral (angio-
graphic access site) arm served as control for 5 minutes; and
ﬁnally (3) after deﬂation of the blood cuff to induce reactive
hyperemia for an additional 5 minutes.
The reactive hyperemia index (RHI) was calculated as a
measure of reactive hyperemia by the ratio of the post- over
preocclusive average amplitude of the RH-PAT signal, nor-
malized for the control arm to compensate for possible
concurrent nonendothelial-dependent systemic alterations in
vascular tone. An exact description of the RH-PAT measure-
ments was previously published.16 Because of skewness of
the data, we described the natural logarithm of RHI.17 A
decreased endothelial function was deﬁned as RHI <1.67,18
which resulted in a logarithmic RHI <0.51.
Patient Symptoms and Clinical Follow-Up
A complete overview of the methods used to assess the
occurrence and severity of angina (Seattle Angina Questionnaire
and Canadian Cardiovascular Society grading), dyspnea
(Borg Dyspnea Scale), and heart failure (New York Heart
Association Functional class) is described in Data S1.
Major adverse clinical events (MACE) were prospectively
collected between the index event and 1.5-year follow-up.
MACE was deﬁned as death and recurrent myocardial
infarction. As a safety objective, we compared the occurrence
and severity of bleedings between both groups. The severity
of bleeding was classiﬁed by the Bleeding Academic Research
Consortium criteria.19 A blinded clinical study investigator
performed the adjudication of events.
Statistical Analysis
The REDUCE-MVI trial had a superiority design with a power of
80% to detect a between-group difference in IMR of 7 (arbitrary
unit) with an SD of 12 in favor of the ticagrelor group at 1-month
follow-up. Details of the sample size calculation are provided in
Data S2. SPSS Statistics, version 22 (IBM Corp, Armonk, NY)
was used to perform statistical analyses. For the current study,
an intention-to-treat (ITT) analysis was used to assess the
difference in outcome measures in patients randomized to
ticagrelor versus prasugrel maintenance therapy. We prespec-
iﬁed the per-protocol (PP) analysis for secondary outcomes in
the original protocol. PP analyses for all end points during 1-year
follow-up were performed in those patients who did not switch
or stop their randomized P2Y12 therapy before 1 year. PP
analyses for 1.5-year follow-up involved the subgroup of
patients included in the 1-year follow-up PP analysis that no
longer received a P2Y12 inhibitor at 1.5-year follow-up.
A complete overview of the statistical analysis methods
can be found in Data S3. Continuous normally distributed data
were reported as meanSD and non–normally distributed
data as median (interquartile range). Dichotomous data were
described as number (%). To assess between-group differ-
ences in continuous variables, an independent t test or Mann–
Whitney U test was used as appropriate. Paired analyses were
performed with the paired sample t test or Wilcoxon signed-
rank test as appropriate. To assess between-group differ-
ences in categorical variables, a Pearson chi-square test was
used, and results were summarized as numbers (%). Paired
analyses with dichotomous variables were performed by the
McNemar test. A linear mixed-model analysis was used to
compare changes in mean RHI over time between treatment
groups. Generalized estimating equations were used to
compare changes in proportion of patients with decreased
RHI value over time between treatment groups. Time to MACE
was visualized by Kaplan–Meier curve and compared between
groups using the log-rank test. A hazard ratio was calculated,
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with prasugrel as the reference group. Statistical signiﬁcance
was assumed when 2-sided P was <0.05.
Results
Study Population and Treatment Strategy
Between May 2015 and October 2017 a total of 110 patients
with STEMI were randomized to either ticagrelor (n=56) or
prasugrel (n=54) maintenance therapy. Baseline and procedu-
ral characteristics of the total study population during the index
procedure are described in Tables S2 and S3, respectively. Two
patients withdrew informed consent before the primary end
point. The total study population therefore consisted of 108
patients (ticagrelor [n=55] versus prasugrel [n=53]). Figure 1
represents the study ﬂowchart during the conduct of the study.
Figure S1 represents the study ﬂowchart of the patients
included in the per-protocol analysis at 1 year (n=84) and at 1.5
years (n=77), and Table S4 demonstrates the PP patient
characteristics at 1-year follow-up. There was no difference in
time between ticagrelor loading dose and the start of the index
procedure (55 [39–70] minutes in the ticagrelor group versus
50 [36–71] minutes in the prasugrel group; P=0.55)
One-year follow-up was performed at 11.80.5 months
and 1.5-year follow-up at 18.61.4 months. There were no
relevant differences in patient characteristics, medication use
or laboratory values at 1-year follow-up in patients random-
ized to ticagrelor versus prasugrel maintenance therapy
(Table 1). During the conduct of the study, 9% of patients
randomized to ticagrelor switched to either prasugrel or
clopidogrel, and 5% of patients randomized to prasugrel
switched to ticagrelor or clopidogrel for various reasons
(Table S5). A total of 8% of patients stopped with their
randomized P2Y12 inhibitor before 1-year follow-up without
replacement of another P2Y12 inhibitor. There were no
signiﬁcant differences between patients initially randomized
to ticagrelor versus prasugrel in cessation/switch of the
initially randomized P2Y12 treatment (P=0.44). At 1.5-year
follow-up, 11% of patients were still on P2Y12 inhibition
therapy: 4% received ticagrelor, 2% received prasugrel, and 6%
received clopidogrel maintenance therapy.
Platelet Inhibition
In the ITT analysis, there were no signiﬁcant differences
between the ticagrelor versus prasugrel group in platelet
Patients included and 
randomized in the 
REDUCE-MVI trial (n=110)
Randomized to ticagrelor 
maintenance therapy (n=56)
Randomized to prasugrel 
maintenance therapy (n=54)
Follow-up at 1 month (n=54)
- Patient withdrew consent (n=1)
- Deceased (n=1)
Follow-up at 1 month (n=51)
- Patient withdrew consent (n=1)
- Deceased (n=2)
Follow-up at 1 year (n=53)
- Lost to follow-up* (n=1)
Follow-up at 1 year (n=51)
Follow-up at 1.5 year (n=51)
- Lost to follow-up* (n=2)
Follow-up at 1.5 year (n=49)
- Lost to follow-up* (n=1)
- Deceased (n=1)
Switch of P2Y12 therapy in the  
ticagrelor group (n=5)
- Switched to clopidogrel (n=4)
- Switched to prasugrel (n=1)
Switch of P2Y12 therapy in the 
prasugrel group (n=1)
- Switched to clopidogrel (n=1)
Switch of P2Y12 therapy in the  
ticagrelor group (n=5)
- Switched to clopidogrel (n=5)
Switch of P2Y12 therapy in the 
prasugrel group (n=4)
- Switched to clopidogrel (n=2)
- Switched to ticagrelor (n=2)
Figure 1. Study enrollment and participation ﬂowchart. *In these patients we did retrieve the survival status at 1.5-year follow-up, and we
therefore also included them in the ﬁnal analysis.
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inhibition or reactivity during the index procedure, at 1 month
or at 1 year (Table 2, Figure 2A and 2B). In the total study
population, platelet inhibition was lower (61 [42–81]
versus 83 [61–95]; P<0.001) and PRU was higher (84
[44–132] versus 38 [12–84]; P<0.001) at 1 month
compared with 1 year (Figure 3A and 3B). At 1-year
follow-up, 79% of patients randomized to ticagrelor had
low platelet reactivity (<85) versus 71% in the prasugrel
group (P=0.39). A total of 7% of patients randomized to
ticagrelor had high platelet reactivity (>208) versus 7% in
the prasugrel group (P=0.95).
In the PP analysis, platelet inhibition at 1-year follow-up
was signiﬁcantly higher in patients randomized to ticagrelor
compared with prasugrel (Table 3, Figure 2C and 2D). Fewer
patients had PRU <95 at 1-month versus 1-year follow-up
(53% versus 91%; P<0.001). Figure 3C and 3D demonstrates
the PP platelet inhibition in the total study population from the
index procedure to 1-year follow-up.
Table 1. Patient Characteristics at 1-Year Follow-Up
Ticagrelor (n=53) Prasugrel (n=51) P Value
Time to 1-y follow-up (d), meanSD 3597 36019 0.64
Age at initial admission, y, meanSD 60.110.4 61.28.8 0.54
Male, n (%) 46/53 (86.8) 42/51 (82.4) 0.53
Systolic blood pressure (mm Hg), meanSD 13416 13517 0.78
Diastolic blood pressure (mm Hg), meanSD 8111 8013 0.77
Heart rate (bpm), meanSD 6414 6611 0.59
Medication at follow-up
P2Y12 inhibitor, n (%) 49/53 (92.5) 46/51 (90.2) 0.68
Acetylsalicylic acid, n (%) 51/53 (96.2) 48/51 (94.1) 0.62
Oral anticoagulants, n (%) 1/53 (1.9) 1/51 (2.0) 0.98
b-Blocker, n (%) 44/53 (83.0) 37/51 (72.5) 0.20
ACE-i, n (%) 31/53 (58.5) 29/51 (56.9) 0.87
ARB, n (%) 9/53 (17.0) 10/51 (19.6) 0.73
Lipid lowering medication, n (%) 48/53 (90.6) 47/51 (92.2) 0.77
Long acting nitrate, n (%) 2/53 (3.8) 1/51 (2.0) 0.58
CCB, n (%) 4/53 (7.5) 3/51 (5.9) 0.74
Diuretics, n (%) 2/53 (3.8) 6/51 (12.0) 0.12
Diabetes mellitus medication, n (%) 5/53 (9.4) 3/51 (5.9) 0.50
Anti-inflammatory drugs, n (%) 3/53 (5.7) 5/51 (9.8) 0.43
Laboratory values
Hemoglobin (mmol/L), meanSD 9.00.7 8.90.8 0.45
Hematocrit (L/L), meanSD 0.430.04 0.430.04 0.84
Platelet count (9109/L), meanSD 242.561.9 235.050.1 0.51
Total leukocyte count (9109/L), median (IQR) 6.4 (5.7–7.9) 7.0 (5.8–8.1) 0.42
Total cholesterol (mmol/L), meanSD 3.40.9 3.71.1 0.18
HDL (mmol/L), meanSD 1.20.4 1.30.4 0.35
LDL (mmol/L), median (IQR) 1.7 (1.2–2.0) 1.6 (1.1–2.2) 0.75
Triglycerides (mmol/L), median (IQR) 1.4 (2.1–0.9) 1.4 (1.0–2.0) >0.99
CRP (mg/L), median (IQR) 2.5 (2.5–2.5) 2.5 (2.5–2.5) 0.88
LDH (U/L), median (IQR) 197 (182–220) 194 (182–228) 0.99
Glucose (mmol/L), median (IQR) 5.5 (5.0–6.5) 5.3 (4.9–6.1) 0.61
NT-proBNP (ng/L), median (IQR) 90 (43–340) 97 (49–243) 0.81
ACE-i indicates angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CRP, C-reactive protein; HDL, high-density lipoprotein; IQR,
interquartile range; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
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Peripheral Endothelial Function
In the ITT analysis, there were no signiﬁcant differences
in mean RHI between patients randomized to ticagrelor
versus prasugrel at individual time points (Figure 4). At 1-
year follow-up, RHI in the ticagrelor group was 0.660.26
versus 0.610.28 in the prasugrel group (P=0.31). In
patients with ticagrelor maintenance therapy, average RHI
signiﬁcantly improved (P=0.03), while in patients with
prasugrel maintenance therapy, RHI did not change
(P=0.88) over time. However, slopes were not found to differ
between groups (P=0.16). There was no difference in the
number of patients with decreased RHI between patients
randomized to ticagrelor versus prasugrel in the acute
setting (43% versus 48%; P=0.58), at 1-month (41% versus
29%; P=0.23), at 1-year (26% versus 31%; P=0.57) or at 1.5-
year follow-up (33% versus 30%; P=0.76). The number of
patients with impaired RHI values decreased from acute to 1
year (P=0.05) in the ticagrelor group, while in the prasugrel
group it did not change (P=0.30). In the total study
population, RHI was signiﬁcantly lower in the acute setting
compared with 1.5-year follow-up (0.540.33 versus
0.640.30; P=0.03). There were signiﬁcantly more patients
with lower RHI in the acute setting versus 1-year (47% versus
39%; P=0.03) and 1.5-year (47% versus 42%; P=0.04) follow-
up. The improvement in RHI over time (P=0.098) in the total
study population was described in Figure S2.
In the PP analysis, there were no signiﬁcant between-group
differences in mean RHI at all time points, but as in ITT
analysis, RHI signiﬁcantly improved over time in patients
randomized to ticagrelor (P=0.04), while it did not in patients
randomized to prasugrel (P=0.56) (Figure S3). RHI did not
signiﬁcantly change after cessation of the P2Y12 inhibitor in
patients randomized to ticagrelor (0.620.31 at 1 year
versus 0.620.38 at 1.5-year; P=0.90) or prasugrel
(0.670.27 at 1 year versus 0.680.29 at 1.5 year;
P=0.86). The improvement in RHI over time in the total study
population was described in Figure S2.
Clinical and Patient Reported Outcome
In the ITT analysis, there were no between-group differences
in the occurrence or severity of dyspnea or angina pectoris at
follow-up (Tables 4 and 5). The number of patients with an
increased New York Heart Association Functional score (New
York Heart Association Functional score >1) at 1.5-year
follow-up did not differ between patients randomized to
ticagrelor versus prasugrel (13 [26%] versus 13 [27%];
P=0.91). There were no patients with stroke and 8 patients
with myocardial infarction (7.8% in the ticagrelor group versus
8.2% in the prasugrel group; P=0.95). There were 22 patients
hospitalized during our study (17.0% in the ticagrelor group
versus 21.6% in the prasugrel group; P=0.55; reasons for
hospitalization are described in Table S6). The combined end
point of MACE at 1.5 years was not signiﬁcantly different in
patients randomized to ticagrelor versus prasugrel (10%
versus 14%; P=0.54; Table 5). The hazard ratio for MACE at
1.5-year follow-up with prasugrel as reference group was 0.80
(0.25–2.62), with P=0.72 (Figure 5). During the conduct of
the study, 50% of patients had either an actionable minor or
major bleeding (Bleeding Academic Research Consortium >2).
There was no signiﬁcant between-group difference in bleed-
ings in patients randomized to ticagrelor versus prasugrel
(47% versus 63%, P=0.10). The majority of bleedings were
nonactionable Bleeding Academic Research Consortium 1
bleedings, and there was no signiﬁcant difference in Bleeding
Academic Research Consortium >1 bleeding score between
patients randomized to ticagrelor versus prasugrel mainte-
nance therapy (Tables 4 and 5).
Also in the PP analysis, there were no signiﬁcant between-,
group differences in patient symptoms, MACE or bleedings
(Table S7). The between-group relative difference (%) and risk
(ratio) for clinical discrete outcomes is demonstrated in Table S8.
Discussion
The current long-term follow-up study of the REDUCE-MVI trial
reports platelet inhibition, peripheral endothelial function, and
Table 2. ITT Platelet Inhibition and Platelet Reactivity
Ticagrelor (n=55) Prasugrel (n=53) P Value
PRU, median (IQR)
Index procedure 185 (87–227) 176 (102–236) 0.72
30 d 91 (43–145) 76 (51–119) 0.63
1 y 31 (10–66) 44 (20–97) 0.20
Inhibition (%), median (IQR)
Index procedure 3 (0–51) 0 (0–39) 0.30
30 d 59 (30–83) 63 (46–78) 0.75
1 y 87 (68–96) 79 (59–92) 0.13
LPR (<85), n (%)
Index procedure* 10 (22.2%) 9 (18.8%) 0.68
30 d† 22 (45.8%) 26 (54.2%) 0.41
1 y‡ 34 (79.1%) 32 (71.1%) 0.39
HPR (>208), n (%)
Index procedure* 19 (41.3%) 19 (39.6%) 0.87
30 d† 4 (8.3%) 0 (0.0%) 0.04
1 y‡ 3 (7.0%) 3 (6.7%) 0.95
ITT analysis in the total study population of 108 patients. HPR indicates high platelet
reactivity; IQR, interquartile range; ITT, intention-to-treat; LPR, low platelet reactivity;
PRU, platelet reactivity unit.
*ITT analysis; ticagrelor n=45 and prasugrel n=48.
†ITT analysis; ticagrelor n=48 and prasugrel n=48.
‡ITT analysis; Ticagrelor n=43 and Prasugrel n=45.
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clinical outcome up to 1.5 years in patients with STEMI
randomized to ticagrelor versus prasugrel maintenance ther-
apy. While the ITT analyses did not reveal between-group
differences in platelet inhibition, peripheral endothelial func-
tion, the occurrence of patient reported symptoms, bleedings,
or MACE up to 1.5 years, the PP analysis revealed a
signiﬁcantly higher platelet inhibition at 1-year follow-up in
patients randomized to ticagrelor versus prasugrel; an
increase in platelet inhibition from 1-month to 1-year follow-
up; a signiﬁcant improvement in peripheral endothelial
function from acute to long-term follow-up in patients
randomized to ticagrelor, which persisted after cessation,
and which did not occur in patients randomized to prasugrel;
and a signiﬁcantly lower peripheral endothelial function in the
acute setting versus 1.5-year follow-up.
The multicenter PRAGUE-18 (Comparison of Prasugrel and
Ticagrelor in the Treatment of Acute Myocardial Infarction)
trial randomized patients with an acute coronary syndrome
(ACS) to either ticagrelor or prasugrel maintenance therapy in
the ﬁrst month following primary percutaneous coronary
intervention and reported an equivalent efﬁcacy and safety
between both P2Y12 inhibitors.
20 Present guidelines therefore
recommend using either ticagrelor or prasugrel as mainte-
nance therapy in patients presenting with STEMI.1 It has been
suggested that ticagrelor may increase adenosine levels,
predominantly at sites of ischemia and tissue injury, by
blockage of the equilibrative nucleoside transporter-1 trans-
porter and thus inhibiting adenosine uptake by red blood
cells,4,5 which we could not conﬁrm in the acute setting and
up to 1 month in the REDUCE-MVI trial.8 Below, we discuss
Figure 2. Platelet inhibition and reactivity in patients randomized to ticagrelor vs prasugrel. In the intention to treat analysis (A and B), we
included the total study population of 108 patients. The per-protocol analysis (C and D) was performed in 84 patients who did not switch or stop
their randomized P2Y12 therapy before 1-year follow-up. 3A (ITT) and C (PP) indicate the platelet inhibition, and 3B (ITT) and D (PP) indicate the
platelet reactivity in patients randomized to ticagrelor vs prasugrel maintenance therapy at 3 different time points. The line in the boxplots
indicates the median, and the cross indicates the mean. PP indicates per-protocol; PRU, platelet reactivity unit; ITT, intention to treat.
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the long-term effects of ticagrelor versus prasugrel mainte-
nance therapy on platelet inhibition, endothelial function, and
clinical outcome.
Platelet Inhibition
The REDUCE-MVI trial reported no signiﬁcant difference in
platelet inhibition from the index event to 1-month follow-up
between patients randomized to ticagrelor compared with
prasugrel maintenance therapy.8 The loading dose of ticagrelor
given to all patients in the acute setting could have led to a
similar platelet inhibition in the acute phase, and because
platelet inhibition in the acute and subacute setting was
impaired, this could have diluted between-group differences.
In the current long-term follow-up study, we demonstrated
higher platelet inhibition at 1 year in the ticagrelor versus
prasugrel group, which is in line with a large meta-analysis.21
A possible mechanism that could explain the higher platelet
inhibition in the ticagrelor group is the 24-hour systemic
exposure of a direct active compound of ticagrelor versus the
Figure 3. Platelet inhibition and reactivity in the total study population. In the intention-to-treat analysis (A and B), we included the total study
population of 108 patients. The per-protocol analysis (C and D) was performed in 84 patients who did not switch or stop their randomized P2Y12
therapy before 1-year follow-up. A-C indicates the platelet inhibition, and B-D indicates the platelet reactivity in the total study population at 3
different time points. The line in the boxplots indicates the median, and the cross indicates the mean. PRU indicates platelet reactivity unit.
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short plasma exposure (2–4 hours) of the active metabolite of
thienopyridines.22 Furthermore, ticagrelor is a direct-acting
drug that binds reversibly to the P2Y12 receptor, while
prasugrel is a prodrug that binds irreversibly to the P2Y12
receptor.23 In addition, ticagrelor inhibits platelet aggregation
not only by P2Y12 antagonism but also via adenosine.
24 In line
with our ﬁndings, Perl et al25 demonstrated an increased
platelet reactivity in patients with STEMI randomized to
prasugrel compared with ticagrelor in the acute setting and up
to 1 month, which was conﬁrmed in a randomized crossover
pharmacodynamics study in stable patients.26 Consequently,
one might speculate that ticagrelor, in comparison with
prasugrel maintenance therapy, reduces the occurrence of
ischemic cardiovascular events at the expense of an increased
bleeding risk. The recently published ISAR-REACT-5 (Intracoro-
nary Stenting and Antithrombotic Regimen: Rapid Early Action
for Coronary Treatment 5) trial, however, demonstrated the
opposite with an increased occurrence of the primary compos-
ite end point of death, myocardial infarction, or stroke at 1-year
follow-up in the ticagrelor versus prasugrel group (9.3% versus
6.9%) in 4018 patients with ACS, without a between-group
difference in the occurrence of major bleeding.27
Additionally, for the ﬁrst time to our knowledge, we report a
lower platelet inhibition at 1 month compared with 1 year in our
total STEMI population. This could be explained either by a
hampered platelet inhibition in the subacute phase after STEMI
(with an associated increased risk of ischemic events) or by an
exceedingly ampliﬁed platelet inhibition after 1 year of P2Y12
inhibitor treatment (with an associated increased bleeding risk).
It has been proposed that in the acute setting of STEMI,
increased levels of reticulated (immature) platelets could
increase platelet reactivity in patients on P2Y12 inhibitor
maintenance therapy.28 Alternatively, increased reactive oxy-
gen species and lipoperoxidation following STEMI are also
predictors for increased platelet reactivity.29 In patients with
stable CAD undergoing elective coronary angiogram, there was
a large interindividual variability in platelet inhibition that was
dependent on pretreatment platelet reactivity,30 which is
increased after STEMI. We hypothesize that in the subacute
phase, these mechanisms are not fully normalized yet and
contribute to the lower platelet inhibition at 1 month and may
furthermore explain the increased risk of ischemic events
following STEMI.31,32 Results by Lynch et al33 support this
hypothesis, demonstrating an increased platelet aggregation
up to 3 months after the ACS index event. In patients with
STEMI, a PRU ≥282 was associated with the occurrence of
ischemic events and death.34 Our study was not powered to
detect a difference in ischemic events or death. On the contrary,
a PRU <95 was associated with a 1.7-fold higher risk of
bleeding.15 Interestingly, we found more patients with a PRU
<95 at 1-year versus 1-month follow-up, which could indicate an
excessive platelet inhibition at 1 year. Concomitantly, it is
clinically of great importance to seek for an optimal balance in
the beneﬁt–risk ratio of platelet inhibition in patients with
STEMI receiving P2Y12 inhibitor maintenance therapy.
Peripheral Endothelial Function
Endothelial dysfunction is not limited to the coronary
arteries,35 and consequently RH-PAT is able to measure the
status of peripheral endothelial function, which correlates
with coronary endothelial function.16 In the acute setting of
STEMI, circulating markers for endothelial injury in peripheral
blood samples are elevated,36 which supports our ﬁnding of
an impaired peripheral endothelial function shortly after the
index event.
We demonstrate an improvement in endothelial function
in patients randomized to ticagrelor, while in patients
randomized to prasugrel, endothelial function did not signif-
icantly improve over time, although it must be noted that the
improvement over time was not signiﬁcantly different
between both groups. Similar to our results, Torngren et al9
also reported an improvement in peripheral endothelial
function in patients with ACS treated with ticagrelor versus
prasugrel. In patients with ACS, ticagrelor improved endothe-
lial function, reduced inﬂammatory cytokines, and increased
Table 3. PP Platelet Inhibition and Platelet Reactivity
Ticagrelor (n=41) Prasugrel (n=43) P Value
PRU, median (IQR)
Index procedure 189 (84–239) 188 (114–237) 0.67
30 d 93 (45–138) 84 (53–122) 0.77
1 y 19 (7–38) 39 (20–73) 0.005
Inhibition (%), median (IQR)
Index procedure 0 (0–50) 0 (0–39) 0.75
30 d 61 (44–82) 60 (44–77) 0.62
1 y 91 (83–97) 82 (65–92) 0.002
LPR (<85), n (%)
Index procedure* 8 (23.5%) 6 (15.8%) 0.41
30 d† 15 (44.1%) 19 (50.0%) 0.62
1 y‡ 29 (96.7%) 29 (78.4%) 0.03
HPR (>208), n (%)
Index procedure* 15 (44.1%) 16 (42.1%) 0.86
30 d† 2 (5.9%) 0 (0%) 0.13
1 y‡ 0 (0%) 1 (2.7%) 0.36
The PP analysis was performed in 84 patients who did not switch or stop their
randomized P2Y12 therapy before 1-year follow-up. HPR indicates high platelet reactivity;
IQR, interquartile range; LPR, low platelet reactivity; PP, per-protocol; PRU, platelet
reactivity unit.
*PP analysis; ticagrelor n=34 and prasugrel n=38.
†PP analysis; ticagrelor n=34 and prasugrel n=38.
‡PP analysis; ticagrelor n=30 and prasugrel n=38.
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circulating progenitor cells.37 The recently published ran-
domized crossover HI-TECH (Hunting for the Off-Target
Properties of Ticagrelor on Endothelial Function in Humans)
trial reported no beneﬁcial effect of ticagrelor over prasugrel
or clopidogrel treatment with regard to peripheral endothelial
function, but they did not assess the potential effects of
ticagrelor on endothelial function over a prolonged time
period.38 The statistical insigniﬁcance between slopes of
both groups could have been attributable to the limited
statistical power to reveal an interaction.
Although we could not demonstrate increased adenosine
plasma levels in the acute and subacute phase in patients
randomized to ticagrelor in the REDUCE-MVI trial,8 this does
not exclude possible stimulation of the endothelium by
adenosine on a local level, resulting in a release of microcir-
culatory vasodilators such as nitric oxide, endothelial hyper-
polarizing factor, and prostacyclins.39,40 Endothelial
hyperpolarizing factor induces endothelium-dependent micro-
circulatory vasodilation by activation of the potassium chan-
nels41 and hence remains an interesting target for future
studies investigating potential effects of ticagrelor on
endothelial function. Additionally, an increase in local con-
centrations of adenosine may lead to microcirculatory
vasodilation by activation of the membrane-bound a2A-
adenosine receptors.42 We hypothesize that these combined
effects of ticagrelor are accountable for the improvement in
endothelial function. Further research is necessary to explore
the potential mechanisms by which ticagrelor augments
peripheral endothelial function.
Patient Symptoms and Clinical Outcome
A well-known drug-speciﬁc side effect of ticagrelor unrelated
to pulmonary function is the manifestation of dyspnea.43,44
We demonstrated a 42% occurrence of dyspnea in the
ticagrelor group versus 35% in the prasugrel group (nonsignif-
icant relative difference of 17%) and a similar severity of
dyspnea at 1 year. Although most patients in our study were
revascularized at 1-month follow-up, we know that (microvas-
cular) angina still occurs in about 40%.45 We hypothesized
that ticagrelor could improve (microvascular) angina by its
previously discussed off-target properties. In our study, we did
not observe between-group differences in the presence or
severity of angina pectoris or heart failure.
In our study, despite limited statistical power, MACE (9% in
the ticagrelor group versus 14% in the prasugrel group) and
the occurrence of bleeding (47% in the ticagrelor group versus
63% in the prasugrel group) at long-term follow-up were not
statistically different in patients randomized to ticagrelor
versus prasugrel. This was in line with a previous
Figure 4. Peripheral endothelial function and improvement in peripheral endothelial function in
patients randomized to ticagrelor vs. prasugrel maintenance therapy. The dashed line represents
the established cutoff value for decreased peripheral endothelial function (RHI <1.67 equals the
natural logarithm RHI <0.51). The line in the boxplots indicates the median and the cross indicates
the mean. The increase in RHI over time was calculated using a mixed-model analysis including
time as main effect. RHI indicates reactive hyperemia index.
DOI: 10.1161/JAHA.119.014411 Journal of the American Heart Association 10
Long-Term Follow-Up of the REDUCE-MVI Trial van der Hoeven et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on March 17, 2020
observational study in 318 patients with STEMI with the
combined end point of major adverse cardiac and cere-
brovascular events at 1-year follow-up.46 As our study was not
powered to detect differences in clinical end points, caution is
needed interpreting our results. The TRITON-TIMI-38 (Trial to
Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial
Infarction 38) showed that prasugrel compared with clopido-
grel prevents ischemic events in patients with ACS, but this
resulted in an accompanying increase in Thrombolysis in
Table 4. Patient Symptoms and Clinical Outcome at 1 Year
Ticagrelor (n=53*) Prasugrel (n=51†) P Value
Angina pectoris, n (%) 11/52 (21.2) 9/51 (17.6) 0.65
CCS class, n (%)
1 9/11 (81.8) 5/9 (55.6) 0.19
2 2/11 (18.2) 3/9 (33.3)
3 0/11 (0.0) 1/9 (11.1)
4 0/11 (0.0) 0/9 (0.0)
SAQ, median (IQR)
Angina frequency 100 (100–100) 100 (100–100) 0.99
Physical limitation 92 (83–100) 100 (75–100) 0.52
Quality of life 71 (58–89) 83 (67–100) 0.10
Angina stability 100 (100–100) 100 (100–100) 0.84
Treatment satisfaction 94 (81–100) 94 (81–100) 0.25
Dyspnea, n (%) 22/52 (42.3) 18/51 (35.3) 0.47
MBS>3, n (%) 6/22 (27.3) 5/18 (27.8) 0.97
Total number of bleedings, n (%) 23/51 (45.1) 30/51 (58.8) 0.17
BARC score, n (%)
0 28/51 (54.9) 21/51 (41.2) 0.33
1 19/51 (37.3) 27/51 (52.9)
2 3/51 (5.9) 2/51 (3.9)
3 0/51 (0.0) 0/51 (0.0)
4 1/51 (2.0) 1/51 (2.0)
5 0/51 (0.0) 0/51 (0.0)
Death, n (%) 1/55 (1.8) 2/53 (3.8) 0.54
Recurrent myocardial infarction, n (%) 4/53 (7.5) 3/51 (5.9) 0.74
Stroke, n (%) 0 (0.0) 0 (0.0) NA
Stent thrombosis, n (%) 0 (0.0) 0 (0.0) NA
Hospitalization, n (%) 6/53 (11.3) 9/51 (17.6) 0.36
Malignant arrhythmia, n (%)‡ 0/52 (0.0) 1/51 (2.0) 0.31
Intercurrent CAG (without the need for PCI), n (%)‡ 3/52 (5.8) 0/51 (0.0) 0.08
PCI, n (%)‡ 3/52 (5.8) 1/51 (2.0) 0.32
Cardiac surgery, n (%)‡ 0/52 (0.0) 0/51 (0.0) NA
MACE, n (%) 5/54 (9.3) 5/53 (9.4) 0.98
We included them in the ﬁnal analysis regarding the occurrence of events (MACE) because we retrieved their survival status at 1 year, except for 1 patient in the prasugrel group for whom
we did not have information regarding recurrent myocardial infarction. BARC indicates Bleeding Academic Research Consortium; CAG, coronary angiography; CCS, Canadian
Cardiovascular Society; IQR, interquartile range; MACE, major adverse clinical events including death and recurrent myocardial infarction; MBS, Modiﬁed Borg Dyspnea Scale; NA, not
applicable; PCI, percutaneous coronary intervention; SAQ, Seattle Angina Questionnaire.
*In the ticagrelor group, 1 patient was deceased and 1 patient was lost to follow-up before 1-year follow-up.
†In the prasugrel group, 2 patients were deceased before 1-year follow-up.
‡There were no additional events reported between 1- and 1.5-year follow-up.
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Myocardial Infarction major bleedings.47 The PLATO (Platelet
Inhibition and Patient Outcomes) trial demonstrated a similar
beneﬁt of ticagrelor over clopidogrel with regard to the
occurrence of ischemic events in patients with ACS, but
without an increase in Thrombolysis in Myocardial Infarction
major bleeding rate.48 On the other hand, it has been reported
that patients with STEMI randomized to ticagrelor have an
increased risk of bleeding comparedwith prasugrel.46 The ISAR-
REACT-5 trial including 41.1% STEMI, 46.2% non–ST-segment–
elevation myocardial infarction (NSTEMI), and 12.7% unstable
angina patients demonstrated reduced occurrence of MACE
without a difference in major bleeding in the prasugrel versus
ticagrelor group in a modiﬁed intention-to-treat analysis.27
Limitations
There are some limitations that should be considered. First of
all, the current study was not powered to detect a signiﬁcant
Table 5. Patient Symptoms and Clinical Outcome at 1.5 Years
Ticagrelor (n=51*) Prasugrel (n=49†) P Value
Angina pectoris, n (%) 10/51 (19.6) 4/49 (8.2) 0.10
CCS class, n (%)
1 5 (50.0) 2/4 (50.0) 0.87
2 4 (40.0) 2/4 (50.0)
3 1 (10.0) 0/4 (0.0)
4 0 (0.0) 0/4 (0.0)
SAQ, median (IQR)
Angina frequency 100 (98–100) 100 (100–100) 0.36
Physical limitation 94 (83–100) 96 (81–100) 0.79
Quality of life 75 (66–92) 83 (67–92) 0.16
Angina stability 100 (80–100) 100 (100–100) 0.29
Treatment satisfaction 94 (81–100) 100 (88–100) 0.08
Dyspnea, n (%) 14/51 (27.5) 18/49 (36.7) 0.32
MBS>3, n (%) 6/14 (42.9) 8/18 (44.4) 0.93
Total number of bleedings, n (%) 24/51 (47.1) 31/50 (63.3) 0.10
BARC score, n (%)
0 27/51 (52.9) 18/50 (36.7) 0.33
1 19/51 (37.3) 26/50 (53.1)
2 4/51 (7.8) 4/50 (8.2)
3 0/51 (0.0) 0/50 (0.0)
4 1/51 (2.0) 1/50 (2.0)
5 0/51 (0.0) 0/50 (0.0)
Ticagrelor (n=55*) Prasugrel (n=53†) P Value
Death, n (%) 1/55 (1.8) 3/53 (5.7) 0.29
Recurrent myocardial infarction,
n (%)
4/51 (7.8) 4/49 (8.2) 0.95
Stroke, n (%) 0 (0.0) 0 (0.0) NA
Stent thrombosis, n (%) 0 (0.0) 0 (0.0) NA
Hospitalization, n (%) 9/53 (17.0) 11/51 (21.6) 0.55
MACE, n (%) 5/52 (9.4) 7/52 (13.5) 0.54
We included them in the ﬁnal analysis regarding the occurrence of events (MACE) because we retrieved their survival status at 1 year, except for 1 patient in the prasugrel group for whom
we did not have information regarding recurrent myocardial infarction. BARC indicates Bleeding Academic Research Consortium; CCS, Canadian Cardiovascular Society; IQR, interquartile
range; MACE, major adverse clinical events including death and recurrent myocardial infarction; MBS, Modiﬁed Borg Dyspnea Scale; NA, not applicable; SAQ, Seattle Angina Questionnaire.
*In the ticagrelor group, 1 patient was deceased and 3 patients were lost to follow-up (of whom 2 patients had hospitalization at 1 year follow-up, which we reported) before 1.5-year
follow-up.
†In the prasugrel group, 3 patients were deceased and 1 patient was lost to follow-up before 1.5-year follow-up.
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between-group difference in secondary outcomes. The sample
size was determined to detect a between-group difference in
the primary end point (IMR at 1 month). Including a PP analysis
in our study could have led to selection bias excluding those
patients who stopped or switched with their initial randomized
medication, although the number of patients deviating from
their randomized medication did not differ between groups. In
the REDUCE-MVI trial, we reported no differences in adenosine
levels in the acute setting up to 1month in patients randomized
to ticagrelor versus prasugrel maintenance therapy. Based on
these ﬁndings, we hypothesized that this would not change
during long-term follow-up, and thus we did not measure
adenosine levels at 1- and 1.5-year follow-up. In the REDUCE-
MVI main paper, we report a longer symptom-to-balloon time
and a higher proportion of patients with hypertension in the
ticagrelor compared with the prasugrel group. These differ-
ences were not statistically signiﬁcant but could have inﬂu-
enced results. Furthermore, we did not test P2Y12-inhibition
adherence by means of ticagrelor or prasugrel levels at follow-
up, but we did assess therapy adherence at follow-up by
questionnaires and platelet inhibition. Because ourmain results
were primarily based on an ITT analysis, a potential lack in
therapy adherence would not alter our main outcomes.
Furthermore, we did not mark the time of intake of the P2Y12
inhibitors on follow-up days, so the time between medication
intake and platelet inhibition tests could vary between patients
and randomized groups. At 1 month, blood samples were
collected during coronary angiography, which may have
inﬂuenced platelet inhibition tests. Finally, the study partici-
pants, treating physicians, and study team were not blinded for
the treatment allocation, and therefore this could have biased
our results. The events, however, were adjudicated by a blinded
study investigator.
Conclusions
In this predeﬁned 1.5-year follow-up study of the REDUCE-MVI
trial, we report platelet inhibition, peripheral endothelial
function, and clinical outcome in patients with STEMI
randomized to ticagrelor versus prasugrel maintenance ther-
apy. Ticagrelor maintenance therapy provided higher platelet
inhibition at 1 year compared with prasugrel. Additionally,
ticagrelor improved peripheral endothelial function from the
acute moment to 1.5-year follow-up, albeit not statistically
different compared with patients on prasugrel maintenance
therapy. Patient symptoms, bleedings, and MACE rate were
Figure 5. Kaplan–Meier curve for the occurrence of MACE at 1.5-year follow-up. The Kaplan–Meier curve
of the MACE-free survival at 1.5-year follow-up in patients randomized to ticagrelor vs. prasugrel
maintenance therapy. The hazard ratio with the 95% CI is for the occurrence of MACE, with prasugrel as
reference. There is no signiﬁcant between-group difference in MACE. FU indicates follow-up; MACE, major
adverse clinical events.
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not statistically different between both groups; however, our
study was not powered to detect differences in clinical
outcome.
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Data S1.  Methods and scores for patient symptom assessment. 
To assess the occurrence and severity of angina pectoris, the Seattle Angina Questionnaire (SAQ), a 19-
item self-administered questionnaire was used1. We report all 5 domains of the SAQ; Physical limitation, 
Angina stability, Angina frequency, Treatment satisfactory and Quality of life. The domain scores range 
from 0-100, with higher scores indicating fewer angina, less physical limitations due to angina and an 
improved quality of live. Additionally, we used the Canadian Cardiovascular Society (CCS) grading to 
grade the severity of angina pectoris (ranging from 0 (asymptomatic) to 4 (angina at rest))2. To assess 
the occurrence and severity of dyspnea, the modified Borg Dyspnea scale (MDS) was used3. The 
dyspnea scale ranges from 0-10 where 0 is no symptoms of dyspnea and 10 is maximal symptoms of 
dyspnea. A MDS>3 was considered as severe dyspnea. To assess the occurrence and severity of heart 
failure, the New York Heart Association Functional (NYHA) classification was used4. Class I represents 
no symptoms, class II symptoms with moderate activity, Class III symptoms with mild activity and Class 
IV symptoms at rest. 
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3) The assumed difference of 7 might be underestimated, based on the recent results of the CV-TIME
trial* (difference in mean microcirculatory resistance was 12.2 between Ticagrelor and Clopidogrel5. In 
the power analysis of the study protocol, the assumed difference was based on peripheral endothelial 
function6 and the SD was based on a study with a different pharmacological agent7. With the current 
evidence of the CV-TIME trial5, the expected difference in microcirculatory resistance between 
Ticagrelor and Prasugrel would be more than 10, which indicated that we did not have to increase the 
number of participants to maintain a power of 80% with the observed standard deviation of 17.2 (taking 
15% loss to follow-up into account). 
Decision of the data safety monitoring board (DSMB) (March 2017): The DSMB would like to state 
that this second Safety Review addressed the charter and protocol driven interim analysis. Based on this 
review, we would like to state that the interim analysis did not raise specific safety concerns. Therefore, 
the REDUCE-MVI study should proceed according to its design. DSMB members: Dr. Jur M. ten Berg 
(member), Prof. Dr. Jan G.P. Tijssen (member), Prof. dr. Freek W.A. Verheugt (Chair).  
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Data S2. Sample size calculation REDUCE-MVI trial.
Initial sample size calculation 
The sample size calculation of the REDUCE-MVI trial was based on a superiority design with a null-
hypothesis that microcirculatory resistance at 1-month follow-up was equal in patients randomized to 
ticagrelor versus prasugrel maintenance therapy. We anticipated that a mean difference in 
microcirculatory resistance of 7 in favour of patients randomized to ticagrelor maintenance was 
considered clinically relevant. To detect this mean difference with a standard deviation (SD) of 12 with 
a power of 80% (two-sided testing at α=0.05), 47 patients in both treatment groups were necessary. 
Furthermore we accounted for a lost to follow-up of patients of 15% leading to a total study population 
of 110 patients. We planned a blinded interim analysis with the data safety monitoring board (DSMB) 
at 50% (n=55) of patient inclusion (see details below). The REDUCE-MVI trial was not powered to 
detect differences in secondary outcomes.  
Interim analysis regarding sample size 
Interim analysis (January 2017): We performed a planned interim analysis (as reported in the study 
protocol) after 50% inclusion to check the assumed SD of the microcirculatory resistance at 1-month 
follow-up (performed by a statistician of the Amsterdam UMC). The observed SD at 1-month follow-
up was 17.2. The re-calculated sample size (with 80% power) was 2 x 96 patients without loss to follow-
up and 2 x 112 with 15% loss to follow-up. The re-calculated power (with the current sample size of 
110 patients) was 56% without loss to follow-up and 50% with loss to follow-up. We also calculated 
the difference in microcirculatory resistance between patients treated with ticagrelor and prasugrel that 
could be detected with the observed SD and 80% power, which was 9.3 without loss to follow-up and 
10 with a 15% loss to follow-up. Despite the higher SD than initially assumed, we do not recommend 
to increase the number of study participants because of the following aspects: 
1) Complexity of the study with lower inclusion rate than expected
2) The power to detect a difference in means of 7 with the observed SD was still acceptable
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Data S3. Complete overview of the statistical analysis methods.
The REDUCE-MVI trial had a superiority design with a power of 80% to detect a between group 
difference in IMR of 7 (arbitrary unit) at 1-month follow-up. Details of the sample size calculation are 
provided in Supplemental Material 3. SPSS Statistics, version 22 (IBM Corp, Armonk, New York) was 
used to perform statistical analysis. For the current manuscript an intention-to-treat analysis was used to 
assess the difference in outcome measures in patients randomized to ticagrelor vs. prasugrel maintenance 
therapy. An additional per-protocol analysis at 1-year was performed in patients who did not switch or 
stop their randomized P2Y12 therapy before 1-year and at 1.5-year including patients who did not receive 
a P2Y12 inhibitor at 1.5-year follow-up. 
Normality was visually assessed by QQ-plots. Continuous normally distributed data were described as 
mean ± standard deviation (SD) and non-normally distributed data as median (interquartile range (IQR)). 
Dichotomous data were described as number (percentage, %). To assess between group differences in 
continuous variables, an independent t-test or Mann-Whitney U test were used as appropriate. Paired 
analyses with continuous data were performed with the paired sample t-test or Wilcoxon signed rank 
test as appropriate. To assess between group differences on nominal categorical variables, a Pearson 
Chi-Square test was used and results were summarized as numbers (%). Paired analyses with 
dichotomous variables were performed by the McNemar test. Mann-Whitney test was used to compare 
groups on ordinal categorical variables. A linear mixed model analysis was used to compare changes in 
mean RHI over time between treatment groups. The mixed model included a random effect for subject 
and fixed effects for treatment group, time and their two-way interaction. Time was included as a 
continuous variable in the model. Separate estimates for changes in mean RHI per year and p-value for 
each of the two treatment groups were obtained from this model. An additional model with the 
interaction term omitted was fitted in order to estimate the mean change in the whole study population. 
Generalized Estimating Equations (GEE) with unstructured working correlation matrix were used to 
compare changes in proportion of patients with decreased RHI value over time between treatment 
groups. The model included time, treatment group and their two-way interaction as predictors. Separate 
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odds ratios for the change in proportion of patients with decreased RHI value for each year increase in 
follow-up time and p-value for the two treatments groups were obtained from this model. An additional 
GEE model with the interaction term omitted was fitted in order to estimate a single odds ratio for the 
change in proportion of patients with decreased RHI value in the whole study population. All analyses 
were performed for 1 and 1.5-year follow-up and separately for the intention-to-treat and per-protocol 
population.. Time to MACE was visualized by the Kaplan-Meier curve, with the log ranked Hazard ratio 
to assess the between group probability of MACE (with prasugrel as the reference group). Statistical 
significance was assumed when P-value was <0.05.  
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Table S1. List of in- and exclusion criteria of the REDUCE-MVI trial. 
Inclusion criteria: 
1. Provision of informed consent
2. Patients presenting with STEMI < 12 hours
3. Successful PCI of the culprit artery with a modern drug eluting stent (DES)
4. The presence of an intermediate stenosis in a non-culprit artery (50-90%)
Exclusion criteria: 
1. Previous history of myocardial infarction
2. Participation in another clinical trial with an investigational product during the preceding 30
days
3. History of cerebrovascular accident (CVA) or ‘transient ischaemic attack’ (TIA)
4. History of intracranial haemorrhage
5. Indication or use of anticoagulant therapy (i.e. acenocoumarol)
6. Severe liver dysfunction (Child-Pughscore 10-15)
7. Congestive heart failure
8. Cardiogenic shock
9. Left ventricular ejection fraction < 35%
10. Bleeding diathesis
11. Age ≥ 75 or < 18
12. Body weight < 60 kg
13. Gout
14. Coagulation disorders
15. Severe pulmonary disease
16. Pregnancy and breast feeding
17. Limited life expectancy
18. Platelet count < 100.000/mm3
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19. History of drug addiction or alcohol abuse in the past 2 years
20. Need for chronic anti-inflammatory drugs
21. Creatinine clearance <30 mL/min or dialysis
22. Presence of a chronic total occlusion (CTO) or left main disease
23. Allergy or contra-indication for ticagrelor or prasugrel
24. Contra-indication for adenosine
25. Patients unable to be followed on site or unable to undergo or contra-indications for MRI
26. Contra-indication for DES
27. Inability to obtain informed consent
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Table S2. Baseline characteristics of total study population at the index event. 
Ticagrelor (n=56) Prasugrel (n=54) P-value
Age (years) 60.2±10.1 61.0±8.8 0.69 
Male, n (%) 49/56 (87.5) 45/54 (83.3) 0.54 
BMI (kg/m2), mean±SD 27.2±3.8 27.8±3.7 0.42 
Symptom to balloon time (min), median (IQR) 191 (126-340) 146 (98-322) 0.10 
Loading dose ticagrelor received, n (%) 56/56 (100.0) 54/54 (100.0) 1.00 
Loading dose-balloon time (min), mean±SD 79±40 77±48 0.18 
Loading dose-IMR time (min), mean±SD 114±39 103±30 0.24 
Medical history 
Hypertension, n (%) 20/56 (35.7) 13/54 (24.1) 0.18 
Diabetes mellitus, n (%) 7/56 (12.5) 4/54 (7.4) 0.37 
Smoking, n (%) 26/56 (46.4) 21/54 (38.9) 0.47 
Hypercholesterolemia, n (%) 12/56 (21.4) 11/54 (20.4) 0.89 
Family history of CAD, n (%) 19/56 (33.9) 23/54 (42.6) 0.35 
Previous PCI, n (%) 3/56 (5.4) 1/54 (1.9) 0.33 
Medication before PPCI 
ASA, n (%) 6/56 (10.7) 3/54 (5.6) 0.30 
Lipid lowering medication, n (%) 12/56 (21.4) 9/54 (16.7) 0.53 
ACE-i or ARB, n (%) 12/56 (21.4) 9/54 (16.7) 0.53 
Beta-blocker, n (%) 8/56 (14.3) 4/54 (7.4) 0.25 
CCB, n (%) 4/56 (7.1) 5/54 (9.3) 0.68 
Laboratory peak values 
CK (U/L), median (IQR) 1040 (441-1913) 1127 (453-2171) 0.86 
CK-MB (µg/L), median (IQR) 86 (28-207) 102 (37-216) 0.73 
Troponin T (µg/L), median (IQR) 1.82 (0.58-5.04) 1.73 (0.38-4.14) 0.39 
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ACE-i: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blocker, ASA: 
acetylsalicylic acid, BMI: body mass index, CAD: coronary artery disease, CCB: calcium channel 
blocker, CK: Creatine kinase, CK-MB: Creatine kinase-MB, IMR: index of microcirculatory resistance, 
IQR: interquartile range, SD: standard deviation, PCI: percutaneous coronary intervention. 
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Table S3. Procedural characteristics of total study population at the index event.
Ticagrelor (n=56) Prasugrel (n=54) P-value
2-vessel disease, n (%) 42/56 (75.0) 41/54 (75.9) 0.91 
3-vessel disease, n (%) 14/56 (25.0) 13/54 (24.1) 0.91 
Cardiogenic shock, n (%) 0/56 (0) 0/54 (0) 1.00 
Radial access, n (%) 53/56 (94.6) 52/54 (96.3) 0.43 
         Angiographic characteristics culprit 
LAD, n (%) 17/56 (30.4) 19/54 (35.2) 0.59 
LCX, n (%) 15/56 (26.8) 13/54 (24.1) 0.74 
RCA, n (%) 24/56 (42.9) 22/54 (40.1) 0.82 
TIMI-flow pre PPCI, n (%) 0 31/56 (55.4) 31/54 (57.4) 0.96 
1 6/56 (10.7) 3/54 (5.6) 
2 13/56 (23.2) 13/54 (24.1) 
3 6/56 (10.7) 7/54 (13.0) 
TIMI-flow post PPCI, n (%) 0 0/56 (0) 0/54 (0) 0.34 
1 2/56 (3.6) 4/54 (7.4) 
2 11/56 (19.6) 4/54 (7.4) 
3 43/56 (76.8) 46/54 (85.2) 
TFC, median (IQR) 41.5 (30.5-65.3) 39.0 (29.0-54.5) 0.58 
cTFC, median (IQR) 37.5 (24.3-56.0) 34.0 (21.8-50.5) 0.40 
MBG, n (%) 0 1/56 (1.8) 0/54 (0) 0.98 
1 7/56 (12.5) 7/54 (13.0) 
2 7/56 (12.5) 8/54 (14.8) 
3 41/56 (73.2) 39/54 (72.2) 
         PCI characteristics culprit 
Stent length (mm), mean±SD 34.07±15.03 32.07±15.6 0.50 
Stent diameter (mm), mean±SD 3.56±0.57 3.66±0.50 0.35 
Thrombectomy, n (%) 4/56 (7.1) 7/54 (13.0) 0.31 
Pre-dilatation, n (%) 33/56 (58.9) 29/54 (53.7) 0.58 
Post-dilatation, n (%) 18/56 (32.1) 13/54 (24.1) 0.35 
Glycoprotein IIb/IIIa inhibitor, n (%) 7/56 (12.5) 6/54 (11.1) 0.92 
cTFC: corrected TIMI frame count, IQR: interquartile range, LAD: left anterior descending 
artery, LCX: left circumflex artery, MBG: myocardial blush grade, PCI: percutaneous 
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coronary intervention, PPCI: primary percutaneous intervention, RCA: right coronary artery, SD: 
standard deviation, TIMI: thrombolysis in myocardial infarction, TFC: TIMI frame count. 
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Table S4. Per protocol analysis of patient characteristics at 1-year follow-up. 
Ticagrelor (n=39) Prasugrel (n=41) P-value
Time to 1-year follow-up (days), mean±SD 359±7 357±14 0.54 
Male, n (%) 36/39 (92.3) 32/41 (78.0) 0.07 
Systolic blood pressure (mmHg), mean±SD 135±15 135±18 0.93 
Diastolic blood pressure (mmHg), mean±SD 82±10 79±14 0.33 
Heart rate (beats / min), mean±SD 65±14 65±12 0.87 
Medication at follow-up 
P2Y12 inhibitor, n (%) 39/39 (100.0) 41/41 (100.0) NA 
Acetylsalicylic acid, n (%) 38/39 (97.4) 40/41 (97.6) 0.97 
Oral anticoagulants, n (%) 0/39 (0) 0/41 (0) NA 
Beta-blocker, n (%) 33/39 (84.6) 30/41 (73.2) 0.21 
ACE-i, n (%) 23/39 (59.0) 25/41 (61.0) 0.86 
ARB, n (%) 6/39 (15.4) 7/41 (17.1) 0.84 
Lipid lowering medication, n (%) 36/39 (92.3) 39/41 (95.1) 0.60 
Long acting nitrate, n (%) 1/39 (2.6) 1/41 (2.4) 0.97 
CCB, n (%) 3/39 (7.7) 3/41 (7.3) 0.95 
Diuretics, n (%) 2/39 (5.1) 5/41 (12.2) 0.26 
Diabetes mellitus medication, n (%) 4/39 (10.3) 3/41 (7.3) 0.64 
Anti-inflammatory drugs, n (%) 2/39 (5.1) 5/41 (12.2) 0.26 
Laboratory values 
Hemoglobin (mmol/L), mean±SD 9.0±0.7 8.8±0.8 0.30 
Hematocrit (L/L), mean±SD 0.43±0.03 0.43±0.03 0.89 
Platelet count (x 109/L), mean±SD 247±69 234±53 0.36 
Total leukocyte count (x 109/L), median (IQR) 6.4 (5.4-8.6) 7.2 (5.9-8.2) 0.42 
Total cholesterol (mmol/L), mean±SD 3.4±0.7 3.7±1.1 0.22 
D
ow
nloaded from
 http://ahajournals.org by on March 17, 2020
HDL (mmol/L), mean±SD 1.1±0.3 1.3±0.4 0.02 
LDL (mmol/L), median (IQR) 1.7 (1.2-2.0) 1.5 (1.1-2.1) 0.52 
Triglycerides (mmol/L), median (IQR) 1.5 (1.0-2.1) 1.3 (1.0-1.9) 0.72 
CRP (mg/L), median (IQR) 2.5 (2.5-2.5) 2.5 (2.5-2.5) 0.73 
LDH (U/L), mean±SD 195 (179-220) 195 (183-232) 0.66 
Glucose (mmol/L), median (IQR) 5.6 (5.0-6.4) 5.3 (4.9-6.4) 0.80 
NT-proBNP (ng/L), median (IQR) 83 (42-275) 101 (51-265) 0.58 
We included the patients eligible for the per protocol analysis at 1-year, minus the deceased 
(n=3) and lost to follow-up (n=1) patients which resulted in a total of 80 patients (ticagrelor n=39, 
prasugrel n=41). ACE-i: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor 
blocker, CCB: calcium channel blocker, CRP: C-reactive protein, HDL: high density lipoprotein, IQR: 
interquartile range, LDH: lactate dehydrogenase, LDL: low density lipoprotein, NT-proBNP: N-
terminal pro-brain natriuretic peptide, SD: standard deviation. 
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Table S5. Reasons for switch of initial randomized P2Y12 treatment strategy. 
Randomized to Inclusion date Date of switch Reason switch Switched to 
Ticagrelor 6-May-2015 12-May-2015 Cardiac thrombus Clopidogrel 
Ticagrelor 31-aug-2015 5-Sep-2015 Nausea after Ticagrelor Prasugrel 
Prasugrel 12-nov-2015 16-Dec-2015 Human error Ticagrelor 
Ticagrelor 12-nov-2015 3-May-2016 Hematomas and bleedings Clopidogrel 
Ticagrelor 9-dec-2015 7-Mar-2016 Surgery persistent pneumothorax Clopidogrel 
Ticagrelor 11-jan-2016 14-Jan-2016 Cardiac thrombus Clopidogrel 
Ticagrelor 26-jan-2016 29-Jan-2016 Atrial fibrillation Clopidogrel 
Ticagrelor 19-May-2016 6-Oct-2016 Hematomas Clopidogrel 
Prasugrel 21-Oct-2016 27-Jun-2017 Hemostaxis Clopidogrel 
Prasugrel 31-Jan-2017 19-Jun-2017 Transient ischemic attack Clopidogrel 
Prasugrel 16-jun-2017 19-June-2017 Atrial fibrillation Clopidogrel 
Ticagrelor 27-jul-2017 9-Aug-2017 Cardiac thrombus Clopidogrel 
Ticagrelor 27-aug-2017 19-Feb-2018 Pruritis of the legs Clopidogrel 
Ticagrelor 9-jan-2016 20-Jul-2016 Percutaneous coronary intervention Clopidogrel 
Prasugrel 8-aug-2017 29-Sep-2017 Human error Ticagrelor 
A total of 15 patients switched their initially randomized P2Y12 inhibitor to another P2Y12 inhibitor 
during the conduct of the study (from inclusion to 1.5-year follow-up).  
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Table S6. Reasons for hospitalization. 
Patient Randomization Reason hospitalization 
1 Ticagrelor Headache, tingling feeling in hands and feet, gastric acid 
2 Ticagrelor Maceration, lung infection 
3 Ticagrelor Chest pain 
4 Prasugrel Dyspnea 
5 Ticagrelor Chest pain 
6 Prasugrel Influenza A 
7 Prasugrel Chest pain 
8 Prasugrel Chest pain 
9 Ticagrelor Cholecystitis 
10 Prasugrel Collaps (vasovagal syncope) 
11 Prasugrel ICD implementation 
12 Ticagrelor Arthritis left shoulder 
13 Prasugrel Chest pain 
14 Prasugrel TIA 
15 Ticagrelor Colon tumor 
16 Prasugrel Hip fracture 
17 Ticagrelor Cellulitis of right groin 
18 Prasugrel Cholecystolithiasis 
19 Ticagrelor Chest pain 
20 Prasugrel Subcapital fracture of the left hip 
ICD: Implantable cardioverter-defibrillator, TIA: transient ischaemic attack. 
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Table S7.  Per protocol analysis of patient symptoms and clinical outcome.
7A. 1-year follow-up Ticagrelor (n=41*) Prasugrel (n=43¥) P-value
Angina pectoris, n (%) 10/38 (26.3) 5/41 (12.2) 0.11 
CCS class, n (%) 1 8/10 (80.0) 2/5 (40.0) 0.10 
2 2/10 (20.0) 2/5 (40.0) 
3 0/10 (0.0) 1/5 (20.0) 
4 0/10 (0.0) 0/10 (0.0) 
SAQ, median (IQR) Angina Frequency 100 (90-100) 100 (100-100) 0.29 
Physical limitation 92 (85-100) 100 (75-100) 0.60 
Quality of life 67 (58-83) 83 (67-100) 0.02 
Angina Stability 100 (95-100) 100 (100-100) 0.49 
Treatment satisfaction 94 (81-100) 100 (88-100) 0.03 
Dyspnea, n (%) 17/38 (44.7) 15/41 (36.6) 0.46 
MBS > 3, n (%) 5/17 (29.4) 5/15 (33.3) 0.81 
Total number of bleedings, n (%) 18/38 (47.4) 25/41 (61.0) 0.23 
BARC score, n (%) 0 20/38 (52.6) 16/41 (39.0) 0.27 
1 16/38 (42.1) 23/41 (56.1) 
2 2/38 (5.3) 1/41 (2.4) 
3 0/38 (0.0) 0/41 (0.0) 
4 0/38 (0.0) 1/41 (2.4) 
5 0/38 (0.0) 0/41 (0.0) 
Death, n (%) 1/41 (2.4) 2/43 (4.7) 0.59 
Recurrent myocardial infarction, n (%) 4/39 (10.3) 3/41 (7.3) 0.64 
Stroke, n (%) 0 (0%) 0 (0%) NA 
Stent thrombosis, n (%) 0 (0%) 0 (0%) NA 
Hospitalization, n (%) 3/39 (7.7) 8/41 (19.5) 0.21 
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Malignant arrhythmia‡, n (%) 0/39 (0.0) 1/41 (2.4) 0.33 
Intercurrent CAG (without the need for PCI)‡, n (%) 3/39 (7.7) 0/41 (0.0) 0.07 
PCI‡, n (%) 2/39 (5.1) 1/41 (2.4) 0.53 
Cardiac surgery‡, n (%) 0/39 (0.0) 0/41 (0.0) NA 
MACE, n (%) 5/40 (12.5) 5/43 (11.6) 0.90 
7B. 1.5-year follow-up Ticagrelor (n=36§) Prasugrel (n=41†) P-value
Angina pectoris, n (%) 5/33 (15.2) 3/37 (8.1) 0.36 
CCS class, n (%) 1 2/5 (40.0) 1/3 (33.3) 0.86 
2 3/5 (60.0) 2/3 (66.7) 
3 0/5 (0) 0/3 (0) 
4 0/5 (0) 0/3 (0) 
5 0/5 (0) 0/3 (0) 
SAQ, median (IQR) Angina Frequency 100 (95-100) 100 (100-100) 0.49 
Physical limitation 97 (85-100) 97 (83-100) 0.96 
Quality of life 75 (67-92) 83 (67-92) 0.42 
Angina Stability 100 (80-100) 100 (100-100) 0.21 
Treatment satisfaction 94 (81-100) 100 (94-100) 0.08 
Dyspnea, n (%) 6/33 (18.2) 13/37 (35.1) 0.11 
MBS > 3, n (%) 3/6 (50.0) 5/13 (38.5) 0.64 
Total number of bleedings, n (%) 16/33 (48.5) 25/38 (65.8) 0.14 
BARC score, n (%) 0 17/33 (51.5) 13/38 (34.2) 0.22 
1 13/33 (39.4) 22/38 (57.9) 
2 3/33 (9.1) 2/38 (5.3) 
3 0/33 (0) 0/38 (0) 
4 0/33 (0) 1/38 (2.6) 
Events at 1.5-year follow-up Ticagrelor (n=36§) Prasugrel (n=41†) P-value
Death, n (%) 1/36 (2.8) 3/41 (7.3) 0.37 
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Recurrent myocardial infarction, n (%) 3/33 (9.1) 3/37 (8.1) 0.88 
Stroke, n (%) 0 (0%) 0 (0%) NA 
Stent thrombosis, n (%) 0 (0%) 0 (0%) NA 
Hospitalization, n (%) 4/33 (12.1) 9/37 (24.3) 0.19 
MACE, n (%) 4/34 (11.8) 6/40 (15.0) 0.69 
* In the ticagrelor group, 1 patient was decreased and 1 patient was lost to follow-up before 1-year 
follow-up. ¥ In the prasugrel group,  2 patients deceased before 1-year follow-up. § In the ticagrelor 
group, 1 patient was deceased and 3 patients were lost to follow-up before 1.5-year follow-up. † In the 
prasugrel group, 3 patients were deceased and 1 patient was lost to follow-up before 2-year follow-up. 
‡ There were no additional events reported between 1 and 1.5 year follow-up. We included them in the 
final analysis because we retrieved their survival status at 1-year. BARC: bleeding academic research 
consortium, CAG: coronary angiography, CCS: canadian cardiovascular society, IQR: 
interquartile range, MACE: major adverse clinical events, MBS: modified borg dyspnea scale, PCI: 
percutaneous coronary intervention, SAQ: seattle angina questionnaire.  
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Table S8. Relative between group difference and risk in discrete outcomes. 
ITT 1 year Ticagrelor 
(n=53) 
Prasugrel 
(n=51) 
Relative 
difference (%) 
Relative 
risk 
P-value
Angina pectoris 21.2% 17.6% -17.0% 1.20 0.65 
Dyspnea 42.3% 35.3% -16.5% 1.20 0.47 
Bleedings 45.1% 58.8% 30.4% 0.77 0.17 
Death 1.8% 3.8% 111.1% 0.47 0.54 
Recurrent myocardial 
infarction 
7.5% 5.9% -21.3% 1.27 0.74 
Stroke 0.0% 0.0% 0.0% NA NA 
Stent thrombosis 0.0% 0.0% 0.0% NA NA 
Hospitalization 11.3% 17.6% 55.8% 0.64 0.36 
Malignant arrhythmia 0.0% 2.0% NA NA 0.31 
Inter current CAG 
(without the need for 
PCI) 
5.8% 0.0% NA NA 0.08 
PCI 5.8% 2.0% -65.5% 2.86 0.32 
Cardiac surgery 0.0% 0.0% 0.0% NA NA 
MACE 9.3% 9.4% 1.1% 0.99 0.98 
PP 1 year Ticagrelor 
(n=41) 
Prasugrel 
(n=43) 
Relative 
difference (%) 
Relative 
risk 
P-value
Angina pectoris 26.3% 12.2% -53.6% 2.17 0.11 
Dyspnea 44.7% 36.6% -18.1% 1.22 0.46 
Bleedings 47.4% 61.0% 28.7% 0.78 0.23 
Death 2.4% 4.7% 95.8% 0.51 0.59 
Recurrent myocardial 
infarction 
10.3% 7.3% -29.1% 1.41 0.64 
Stroke 0.0% 0.0% 0.0% NA NA 
Stent thrombosis 0.0% 0.0% 0.0% NA NA 
Hospitalization 7.7% 19.5% 153.3% 0.40 0.21 
Malignant arrhythmia 0.0% 2.4% NA NA 0.33 
Intercurrent CAG 
(without the need for 
PCI) 
7.7% 0.0% NA NA 0.07 
PCI 5.1% 2.4% -52.9% 2.13 0.53 
Cardiac surgery 0.0% 0.0% 0.0% NA NA 
MACE 12.5% 11.6% -7.2% 1.08 0.90 
ITT 1.5 year Ticagrelor 
(n=51) 
Prasugrel 
(n=49) 
Relative 
difference (%) 
Relative 
risk 
P-value
Angina pectoris 19.6% 8.2% -58.2% 2.38 0.10 
Dyspnea 27.5% 36.7% 33.5% 0.75 0.32 
Bleedings 47.1% 63.3% -34.4% 1.34 0.10 
Death 1.8% 5.7% 216.7% 0.32 0.29 
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Recurrent myocardial 
infarction 
7.8% 8.2% 5.1% 0.95 0.95 
Stroke 0.0% 0.0% 0.0% NA NA 
Stent thrombosis 0.0% 0.0% 0.0% NA NA 
Hospitalization 17.0% 21.6% 27.1% 0.79 0.55 
MACE 9.4% 13.5% 43.6% 0.69 0.54 
PP 1.5 year Ticagrelor 
(n=36) 
Prasugrel 
(n=41) 
Relative 
difference (%) 
Relative 
risk 
P-value
Angina pectoris 15.2% 8.1% -46.7% 1.89 0.36 
Dyspnea 18.2% 35.1% 92.9% 0.52 0.11 
Bleedings 48.5% 65.8% 35.7% 0.74 0.14 
Death 2.8% 7.3% 160.7% 0.38 0.37 
Recurrent myocardial 
infarction 
9.1% 8.1% -11.0% 1.12 0.88 
Stroke 0.0% 0.0% 0.0% NA NA 
Stent thrombosis 0.0% 0.0% 0.0% NA NA 
Hospitalization 12.1% 24.3% 100.8% 0.50 0.19 
MACE 11.8% 15.0% 27.1% 0.79 0.69 
The relative risk/ratio is compared to the ticagrelor group. CAG: coronary angiography, ITT: intention 
to treat analysis, MACE: major adverse clinical events, PCI: percutaneous coronary intervention, PP: 
per protocol analysis, SAQ: seattle angina questionnaire. 
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Patients included and 
randomized in the 
REDUCE-MVI trial (n=110)
Randomized to ticagrelor 
maintenance therapy (n=56)
Randomized to prasugrel 
maintenance therapy (n=54)
Follow-up at 1 month (n=50)
- Patient withdrew consent (n=1)
- Switched to clopidogrel (n=4)
- Switched to prasugrel (n=1)
Follow-up at 1 month (n=52)
- Patient withdrew consent (n=1)
- Switched to clopidogrel (n=1)
Follow-up at 1 year (n=41)
- Switched to clopidogrel (n=5)
- Stopped P2Y12 inhibitor (n=4)
Follow-up at 1 year (n=43)
- Switched to clopidogrel (n=2)
- Switched to ticagrelor (n=2)
- Stopped P2Y12 inhibitor (n=5)
Follow-up at 1.5 year (n=36)
- Received P2Y12 inhibitor at 1.5 
year follow-up (n=5)
Follow-up at 1.5 year (n=41)
- Received P2Y12 inhibitor at 1.5 
year follow-up (n=2)
Deceased in the  ticagrelor group 
(n=1)
Deceased in the prasugrel group 
(n=2)
Per protocol analysis 1.5 year
Lost to follow-up* in the  
ticagrelor group (n=1)
Lost to follow-up*  in the  
prasugrel group (n=1)
Deceased in the prasugrel group 
(n=1)
Lost to follow-up* in the  
ticagrelor group (n=2)
Per protocol analysis 1 year
Figure S1. Study flow chart of patients included in the per-protocol analysis.
For the 1-year analysis, we included 84 patients who did not switch or stop with their initial 
randomized P2Y12 inhibition therapy before 1-year follow-up. For the 1.5-year analysis, we 
included 77 patients (ticagrelor n=36 versus prasugrel n=41) who did not switch or stop with their initial 
randomized P2Y12 inhibition therapy before 1-year follow-up and who did not receive P2Y12 inhibition 
therapy at 1.5-year follow-up. * In these patients we did retrieve the survival status at 1.5-year follow-
up and we therefore included them in the final analysis.  
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Figure S2. Improvement in peripheral endothelial function over time in the total study 
population. 
Peripheral endothelial function and improvement in peripheral endothelial function at different time 
points. In the ITT analysis (A) all patients were included (n=108). In the per-protocol analysis (B) 
we included 77 patients (ticagrelor n=36 versus prasugrel n=41) who did not switch or stop with their 
initial randomized P2Y12 inhibition therapy before 1-year follow-up and who additionally did not 
receive P2Y12 inhibition therapy at 1.5-year follow-up. The dashed line represents the established cut-
off value for decreased peripheral endothelial function (RHI < 1.67, equals the natural logarithm 
RHI < 0.51). The line in the boxplots indicates the median and the cross indicates the mean. The increase 
in RHI over time was calculated using a mixed model analysis including time as main effect. ITT; 
intention to treat, PP; per protocol, RHI; reactive hyperemia index. 
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Figure S3. Per protocol analysis of peripheral endothelial function. 
Peripheral endothelial function and improvement in peripheral endothelial function in patients 
randomized to ticagrelor vs. prasugrel maintenance therapy. In the per-protocol analysis at we 
included 77 patients (ticagrelor n=36 versus prasugrel n=41) who did not switch or stop with their initial 
randomized P2Y12 inhibition therapy before 1-year follow-up and who additionally did not receive 
P2Y12 inhibition therapy at 1.5-year follow-up. The dashed line represents the established cut-off value 
for decreased peripheral endothelial function (RHI < 1.67, equals the natural logarithm RHI < 0.51). 
The line in the boxplots indicates the median and the cross indicates the mean. The increase in RHI over 
time was calculated using a mixed model analysis including time as main effect. RHI: reactive 
hyperemia index.  
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